2024
Patient Characteristics and Practice Variation Associated With New Community Prescription of Benzodiazepine and z‐Drug Hypnotics After Critical Illness: A Retrospective Cohort Study Using the UK Clinical Practice Research Datalink
Mansi E, Rentsch C, Bourne R, Guthrie B, Lone N. Patient Characteristics and Practice Variation Associated With New Community Prescription of Benzodiazepine and z‐Drug Hypnotics After Critical Illness: A Retrospective Cohort Study Using the UK Clinical Practice Research Datalink. Pharmacoepidemiology And Drug Safety 2024, 33: e70056. PMID: 39603606, PMCID: PMC11602247, DOI: 10.1002/pds.70056.Peer-Reviewed Original ResearchConceptsCommunity prescriptionsZ-drugsIllness survivorsRetrospective cohort studyClinical Practice Research Datalink dataPractice variationUK Clinical Practice Research DatalinkClinical Practice Research DatalinkWorsening mental health conditionsCohort studyMultilevel multivariable logistic regressionSurvivors of critical illnessZ-drug prescribingCritical care survivorsPrimary care practicesCritical illnessMental health conditionsZ-drug prescriptionsCritical illness survivorsMultivariate logistic regressionPrescription opioid useCare practicesRisk of adverse eventsHealth conditionsHistory of insomnia
2021
OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
Collaborative T, Curtis HJ, MacKenna B, Walker AJ, Croker R, Mehrkar A, Morton C, Bacon S, Hickman G, Inglesby P, Bates C, Evans D, Ward T, Cockburn J, Davy S, Bhaskaran K, Schultze A, Rentsch CT, Williamson E, Hulme W, Tomlinson L, Mathur R, Drysdale H, Eggo RM, Wong AY, Forbes H, Parry J, Hester F, Harper S, Douglas I, Smeeth L, Goldacre B. OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic. Open Heart 2021, 8: e001784. PMID: 34785588, PMCID: PMC8595296, DOI: 10.1136/openhrt-2021-001784.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsBlood CoagulationBlood Coagulation TestsCOVID-19Drug MonitoringDrug PrescriptionsDrug SubstitutionDrug UtilizationEnglandFactor Xa InhibitorsFemaleHumansMaleMiddle AgedPatient SafetyPractice Guidelines as TopicPractice Patterns, Physicians'Primary Health CareRetrospective StudiesRisk AssessmentRisk FactorsState MedicineWarfarinConceptsWarfarin patientsNational Health ServiceCOVID-19 pandemicNational guidanceCare home residencyINR test resultsRenal function testsFrequent blood testingSafety alertsRoutine clinical dataAtrial fibrillation diagnosisElevated INRMedication changesOral anticoagulantsAnticoagulant therapyCohort studyAppropriate patientsINR testsFunction testsBlood testingPrimary careClinical dataDOACPatientsWarfarinUse of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Forbes H, Eggo RM, Parry J, Hester F, Harper S, Evans SJ, Smeeth L, Douglas IJ, Goldacre B, Collaborative T. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Annals Of The Rheumatic Diseases 2021, 80: 943-951. PMID: 33478953, PMCID: PMC7823433, DOI: 10.1136/annrheumdis-2020-219517.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drugsPrescribed non-steroidal anti-inflammatory drugsRheumatoid arthritis/osteoarthritisArthritis/osteoarthritisCurrent NSAID usersMultivariable-adjusted modelsAnti-inflammatory drugsNSAID prescriptionsNSAID usersGeneral populationCOVID-19Risk of deathNational Health Service EnglandRoutine therapeutic useRoutine clinical dataCohort studyCurrent useCox regressionClinical dataCohort analysisLower riskEvidence of differencesDeath dataTherapeutic useDeath
2019
Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators.
Womack JA, Murphy TE, Rentsch CT, Tate JP, Bathulapalli H, Smith AC, Bates J, Jarad S, Gibert CL, Rodriguez-Barradas MC, Tien PC, Yin MT, Gill TM, Friedlaender G, Brandt CA, Justice AC. Polypharmacy, Hazardous Alcohol and Illicit Substance Use, and Serious Falls Among PLWH and Uninfected Comparators. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 305-313. PMID: 31339866, PMCID: PMC7176040, DOI: 10.1097/qai.0000000000002130.Peer-Reviewed Original ResearchConceptsIllicit substance useHazardous alcoholSerious fallsUninfected comparatorsMedication classesOpioid prescriptionsSubstance useHIV statusMuscle relaxantsRisk factorsVeterans Aging Cohort StudyAging Cohort StudyIllicit substance abuseUnconditional logistic regressionNon-ART medicationsHazardous alcohol useSubstance use/abuseCase-control designKey risk factorsUse/abuseCohort studyMedication countInjury codesDuration of observationBaseline date
2018
Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection
Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert CL, Re VL, Fiellin DA, Justice AC, Tate JP. Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection. Annals Of Epidemiology 2018, 28: 808-811. PMID: 30195616, PMCID: PMC6318448, DOI: 10.1016/j.annepidem.2018.08.007.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionCorporate Data WarehouseChronic HCV infectionC virus infectionPositive predictive valuePredictive valueHCV infectionHCV treatmentVirus infectionVeterans Health Administration Corporate Data WarehouseChronic hepatitis C virus (HCV) infectionStudy periodModern treatment eraRetrospective cohort studyElectronic health record dataPharmacy fill recordsHealth record dataNegative predictive valueElectronic health recordsAntiviral regimenHCV therapyTreatment eraChart reviewCohort studyAntiviral treatment